NCOG-44. NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN A PHASE II STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA

PURPOSE: The neurologic assessment in neuro-oncology (NANO) scale was developed as a standardized metric to objectively measure neurologic function in brain tumor patients to complement radiographic assessment in defining overall outcome. A multicenter, phase 2 study of pembrolizumab with or without...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Neuro Oncol
Main Authors: Nayak, Lakshmi, Molinaro, Annette, Peters, Katherine, Clarke, Jennifer, Jordan, Justin, de Groot, John, Nghiemphu, Phioanh, Kaley, Thomas, Colman, Howard, McCluskey, Christine, Gaffey, Sarah, Smith, Timothy, Cote, David, Severgnini, Mariano, Yearley, Jennifer, Zhao, Qing, Blumenschein, Wendy, Duda, Gabriel, Muzikansky, Alona, Jain, Rakesh, Wen, Patrick, Reardon, David
פורמט: Artigo
שפה:Inglês
יצא לאור: Oxford University Press 2020
נושאים:
Outcome Measures and Neuro-Cognitive Outcomes
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651576/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.582
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים